Duofilm Liquid
Prodotto naturale per la salute autorizzato in Canada
- Titolare
- Haleon US Holdings LLC
- NPN o DIN-HM
- 00370576
- Stato
- Licenza non attiva
- Data della licenza
- 30 novembre 2009
- Data di revisione
- 21 febbraio 2017
- Forma
- Solution semblabe au collodion.
- Via di somministrazione
- Topique
- Tipo di domanda
- DIN de transition
L’analisi delle dosi orali non si applica senza una via esclusivamente orale accertata.
Composizione
| Ingrediente medicinale e fonte | Per unità posologica, secondo la fonte |
|---|---|
| Acide lactique | 16,7 % |
Ingredienti non medicinali
Flexible collodion
Dosi raccomandate in Canada
| Popolazione | Età | Quantità per assunzione | Frequenza |
|---|---|---|---|
Sottopopolazione S/O Tradotto automaticamente dal francese. Vedi l’originaleSous-population S/O | Non precisata Tradotto automaticamente dal francese. Vedi l’originaleNon précisée | Traduzione non disponibile. Testo originale, lingua: francese. 1 Goutte(s) | Traduzione non disponibile. Testo originale, lingua: francese. 24 heures |
Usi autorizzati in Canada
Traduzione non disponibile. Testo originale, lingua: inglese.
For the removal of common warts.Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.
Avvertenze in Canada
Traduzione non disponibile. Testo originale, lingua: inglese.
Cautions and Warnings : DUOFILM® is for external use only. DUOFILM® is extremely flammable and should be kept away from fire or flame. Keep bottle tightly capped when not in use. Store at controlled room temperature away from heat.
Patients should be advised not to inhale the vapour. DUOFILM® may cause eye irritation. Avoid contact with eyes and other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, flush with water for 15 minutes. If discomfort persists, patients should be advised to contact a physician. Avoid exposure to healthy skin. DUOFILM® may cause skin irritation. If undue skin irritation develops, treatment should be discontinued and patients should be advised to contact a physician or pharmacist. Consider alternative treatments if warts cover a large area of the body (more than 5 cm²) due to the potential risk of salicylate toxicity. DUOFILM® is not recommended in patients with peripheral neuropathy except under the supervision of a physician. Oral salicylates taken during or immediately after a viral illness have been associated with Reye's syndrome and hence there is a theoretical risk with topical salicylates. Therefore, do not use in children or teenagers during or immediately after chickenpox, influenza, or other viral infections. It has been reported that salicylates are excreted via breast milk. Patients should be advised to consult a health care physician if discomfort persists. Keep out of the sight and reach of children.
Pregnancy and Lactation
Pregnancy
The safety of DUOFILM® during human pregnancy has not been established. Studies in animals given salicylic acid orally demonstrated embryo-toxicity at high doses. DUOFILM® is not recommended during pregnancy.
Lactation
Salicylates are excreted in human milk. DUOFILM® is not recommended during lactation. If used or administered during lactation, care should be taken to avoid contact with the breast area in order to avoid accidental ingestion by the infant.Traduzione non disponibile. Testo originale, lingua: inglese.
Known Adverse Reactions : Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common (greater than and or equal to 1/10), common (greater than and or equal to 1/100 to less than 1/10), uncommon (greater than and or equal to 1/1000 to less than 1/100) rare (greater than and or equal to 1/10000 to less than 1/1000) and very rare (less than 1/10000).
Clinical Trial Data
Immune system disorders
Common: Rash
Skin and subcutaneous tissue disorders
Very common: Application site reaction, pruritus, burning sensation, erythema, scaling, dryness
Common: Skin hypertrophy
Post-marketing data
Immune system disorders
Rare: Application site hypersensitivity including inflammation
Skin and subcutaneous tissue disorders
Rare: Application site pain and irritation. Application site discoloration/skin discoloration. Exposure to healthy skin can lead to application site blistering and skin exfoliation. Allergic dermatitis.
Interactions
DUOFILM® may increase the absorption of other topically applied medicines. Therefore, concomitant use of DUOFILM® and other topical medicines on the treated area should be avoided.Fonte
Scheda ufficiale Health Canada, licenza 00370576
Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.
Elenco nella revisione ufficiale del (registro: Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze).